Balázs Győrffy
High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML).
Bajrami Saipi M, Ruiba A, Schittenhelm M, Blumenstock G, Győrffy B, Fazio S, Hafner M, Ahrens A, Aldinger L, Aellig V, Kavelaars F, Nombela-Arrieta C, Fend F, Valk P, Driessen C, Kampa-Schittenhelm K. High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML). Cell Death Dis 2024; 15:869.
30.11.2024High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML).
30.11.2024Cell Death Dis 2024; 15:869
Bajrami Saipi Mihada, Ruiba Alessia, Schittenhelm Marcus, Blumenstock Gunnar, Győrffy Balázs, Fazio Serena, Hafner Marlon, Ahrens Anna-Lena, Aldinger Lara, Aellig Vanessa, Kavelaars François G, Nombela-Arrieta César, Fend Falko, Valk Peter J M, Driessen Christoph, Kampa-Schittenhelm Kerstin
Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML).
Schittenhelm M, Kaiser M, Győrffy B, Kampa-Schittenhelm K. Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML). Cell Death Dis 2024; 15:25.
10.01.2024Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML).
10.01.2024Cell Death Dis 2024; 15:25
Schittenhelm Marcus, Kaiser Max, Győrffy Balázs, Kampa-Schittenhelm Kerstin